Catheter Precision, INC 10-Q quarterly reports

Catheter Precision, Inc. reported its Q1 2026 financial results, highlighting increased revenues from its cardiac electrophysiology and private aviation segments following the acquisition of FLYTE.

Catheter Precision reported increased Q3 2025 revenues driven by LockeT sales but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Catheter Precision, Inc. reported increased net losses and negative cash flows for the first half of 2025, despite strategic acquisitions and capital raising efforts, raising substantial doubt about its ability to continue as a going concern.

Catheter Precision's Q1 2025 results reveal increased revenue offset by higher expenses, leading to a net loss and raising concerns about the company's ability to continue as a going concern.

Catheter Precision's Q3 2024 report reveals a net loss of $4.12 million, ongoing financial challenges, and strategic shifts following a merger, while also highlighting new product sales and a recent public offering.

Catheter Precision's Q2 2024 results reveal continued operating losses and a substantial doubt about the company's ability to continue as a going concern.

Catheter Precision's Q1 2024 results show a slight revenue decrease and a significant reduction in operating expenses, alongside ongoing efforts to address financial and operational challenges.